Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick L Locke

Showing results (61-70 of 234) with videos related to

Pageof 24
Sort By:
Blood Advances|April 10, 2020
Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trialStephen J Schuster, Richard T Maziarz, Elisha S Rusch, et al.
Transplantation and Cellular Therapy|February 15, 2025
Awakening from REMS: ASTCT 80/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T CellsFrederick L Locke, Zahra Mahmoudjafari, Partow Kebriaei, et al.
Bone Marrow Transplantation|August 12, 2021
Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipientsAsmita Mishra, Joseph Pidala, Ram Thapa, et al.
Expert Review of Anticancer Therapy|April 22, 2024
Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studiesOlalekan O Oluwole, Sattva S Neelapu, Markqayne D Ray, et al.
Leukemia & Lymphoma|July 7, 2017
Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patientsShalaka S Hampras, Frederick L Locke, Julio C Chavez, et al.
Leukemia & Lymphoma|September 1, 2022
Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphomaOlalekan O Oluwole, Jenny M H Chen, Keith Chan, et al.
Frontiers in Oncology|March 14, 2025
Tumor gene expression signatures associated with outcome in large B-cell lymphoma treated with CD19-directed CAR T-cell therapy (axicabtagene ciloleucel)Yuan Tian, Justin Budka, Frederick L Locke, et al.
British Journal of Haematology|August 15, 2019
Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapyHamza Hashmi, Christina Bachmeier, Julio C Chavez, et al.
American Journal of Hematology|June 19, 2019
Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cellsMohamed A Kharfan-Dabaja, Michael D Jain, Sonikpreet Aulakh, et al.
Transplantation and Cellular Therapy|September 10, 2025
Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed/Refractory Large B-cell LymphomaMiguel-Angel Perales, Olalekan O Oluwole, Anik R Patel, et al.
Pageof 24

Showing results (61-70 of 234) with videos related to

Sort By:
Pageof 24
Blood Advances|April 10, 2020
Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trialStephen J Schuster, Richard T Maziarz, Elisha S Rusch, et al.
Transplantation and Cellular Therapy|February 15, 2025
Awakening from REMS: ASTCT 80/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T CellsFrederick L Locke, Zahra Mahmoudjafari, Partow Kebriaei, et al.
Bone Marrow Transplantation|August 12, 2021
Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipientsAsmita Mishra, Joseph Pidala, Ram Thapa, et al.
Expert Review of Anticancer Therapy|April 22, 2024
Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studiesOlalekan O Oluwole, Sattva S Neelapu, Markqayne D Ray, et al.
Leukemia & Lymphoma|July 7, 2017
Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patientsShalaka S Hampras, Frederick L Locke, Julio C Chavez, et al.
Leukemia & Lymphoma|September 1, 2022
Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphomaOlalekan O Oluwole, Jenny M H Chen, Keith Chan, et al.
Frontiers in Oncology|March 14, 2025
Tumor gene expression signatures associated with outcome in large B-cell lymphoma treated with CD19-directed CAR T-cell therapy (axicabtagene ciloleucel)Yuan Tian, Justin Budka, Frederick L Locke, et al.
British Journal of Haematology|August 15, 2019
Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapyHamza Hashmi, Christina Bachmeier, Julio C Chavez, et al.
American Journal of Hematology|June 19, 2019
Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cellsMohamed A Kharfan-Dabaja, Michael D Jain, Sonikpreet Aulakh, et al.
Transplantation and Cellular Therapy|September 10, 2025
Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed/Refractory Large B-cell LymphomaMiguel-Angel Perales, Olalekan O Oluwole, Anik R Patel, et al.
Pageof 24